For years now, consumer advocates have blistered Big Pharma companies with ongoing criticism of the secretive nature of their drug development work. Now GlaxoSmithKline (NYSE: GSK) is trying a whole new approach, creating a unique open-source development program that will offer up 13,500 chemical compounds that have the potential to throttle the parasites that cause malaria.
Three Web sites will host the treasure trove of information, according to an in-depth feature from the Wall Street...